The big numbers in the BMY-PFE Apixaban partnership pertained to multiple indications, not just ACS. Notwithstanding the failure in ACS, Apixaban will likely be a big-selling drug in AF/stroke prevention, where its efficacy was sufficiently strong for the phase-3 AVERROES study to be stopped early (#msg-54576974).
Thus, while the BMY-PFE Apixaban partnership is a yardstick of sorts for M118, it is not directly comparable because the Apixaban development program has a much broader scope—and a much bigger price tag—than what is envisioned for M118.
Perhaps a better comparator for what can be expected from an M118 partnership is the 2009 MRK-Portola deal for Betrixaban, which is geared to one indication (#msg-39388813). MNTA might be able to do somewhat better than Portola inasmuch as MNTA’s technology is proven and M118, unlike Betrixaban, is sui generis.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.